Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus to report Q4 and full year 2025 results on February 24, 2026

Neutral Impact 2 of 5 earnings Written later

Supernus Pharmaceuticals said it will report fourth quarter and full year 2025 financial and business results after the market closes on February 24, 2026, and will host a conference call and webcast that day at 4:30 p.m. ET. The filing is a scheduling notice only and contains no financial results, so it does not indicate how the company performed.

Key points

  • Results release scheduled for after market close on Tuesday, February 24, 2026
  • Conference call and webcast set for February 24, 2026 at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec
  • Filing contains no revenue, profit or guidance figures

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECFeb 12, 2026, 4:16 PM ET
Accession number0001356576-26-000002

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.